OakChart

Longeveron Inc

LGVNHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET

3.30+0.46 (16.20%)
2026-11-12 03:46 CET
Market cap
10.52 USD m
Revenue, TTM
1.19 USD m
Net income, TTM
-23.47 USD m
Free cash flow, TTM
-20.53 USD m
EPS diluted, TTM
-10.15
P/E
-
Compare

Price

LGVN against its 20, 50 and 200-day averages
2050200miss
2.004.006.008.0010.00722K1.4MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26LGVNclose 3.3020-day 1.7950-day 3.08200-day 6.493.3052w low

73.2% under the 52-week high of 12.30 on 7 Apr 2026. 52-week low 1.31 on 19 Oct 2026. Last 15 sessions, 134.0% high to low

Volume 1.12× normal · the line is the 50-bar volume average

Profile

LGVN
52-week range, 18% of the way up
1.3112.30

Longeveron, Inc. is a clinical stage biotechnology company, which engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young, healthy, adult donors. The company was founded by Joshua M. Hare and Donald M. Soffer on October 9, 2014 and is headquartered in Miami, FL.

Employees38
IPOFeb 12, 2021
Beta0.79
ATR, 14d0.29
Rel volume1.12
Short float6.31%
Insider own21.91%
Inst own16.63%

Snapshot

6 groups

Valuation

Index-
Market Cap10.52M
Enterprise Value1.02M
Income-23.47M
Sales1.19M
Book/sh3.28
Cash/sh3.16
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees38
IPOFeb 12, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S8.84
P/B1.01
P/C1.04
P/FCF-
EV/EBITDA-
EV/Sales0.85
Quick Ratio2.63
Current Ratio2.63
Debt/Eq0.06
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-10.15
EPS next Y-5.80
EPS next Q-1.70
EPS this Y44.19%
EPS next Y19.44%
EPS next 5Y24.28%
EPS past 3/5Y47.61% 8.03%
Sales past 3/5Y-0.63% -26.60%
EPS Y/Y TTM20.66%
Sales Y/Y TTM-42.74%
EPS Q/Q42.21%
Sales Q/Q-9.18%
EarningsAug 12 AMC
EPS/Sales Surpr.-8.57% -11.96%

Ownership

Insider Own21.91%
Insider Trans0.00%
Inst Own16.63%
Inst Trans-0.23%
ROA-145.64%
ROE-203.61%
ROIC-225.67%
Gross Margin-15.92%
Oper. Margin-1992.84%
Profit Margin-1977.59%
SMA2083.97%
SMA507.08%
SMA200-49.19%
Trades-

Technical

Shs Outstand3.03M
Shs Float2.49M
Short Float6.31%
Short Ratio1.33
Short Interest0.16M
52W High12.30 -73.17%
52W Low1.31 151.91%
Volatility18.00% 13.87%
ATR (14)0.29
RSI (14)69.86
Beta0.79
Rel Volume1.12
Avg Volume117.76K
Volume132,330

Performance

Perf Week85.39%
Perf Month53.49%
Perf Quarter-52.69%
Perf Half Y-56.29%
Perf YTD-34.78%
Perf Year-53.98%
Perf 3Y-98.19%
Perf 5Y-99.05%
Perf 10Y-
Recom3.00
Target Price4.25
Prev Close2.84
Price3.30
Change %16.20%

Analyst ratings

latest 1 of 1
DateActionAnalystRating changeTargetImplied
Dec 06, 2024InitiatedRROTH MKMBuy$10+203.0%

Peers

Mkt cap
TickerCompanyMkt cap
MESOMesoblast Ltd ADR1.78B
PLURPluri Inc15.13M
BCDABioCardia Inc13.95M
CELZCreative Medical Technology Holdings Inc4.79M
BRTXBioRestorative Therapies Inc2.15M
CAPRCapricor Therapeutics Inc652.32M
FBLGFibroBiologics Inc6.63M
CELUCelularity Inc24.37M
LCTXLineage Cell Therapeutics Inc280.72M
VCELVericel Corp3.03B

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B

News

latest 14 of 196
  • Longeveron Announces Engagement of Lucid Capital Markets (GlobeNewswire)
  • Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS) (GlobeNewswire)
  • Longeveron to Participate in Three Longevity/Aging Investment Conferences (GlobeNewswire)
  • Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug (BioPharma Dive) -8.12%
  • Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS) (GlobeNewswire) -59.43%
  • Longeveron to Present at the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
  • Longeveron Announces 1-for-10 Reverse Stock Split (GlobeNewswire) -18.84%
  • Longeveron Appoints Nirav Jhaveri as Chief Financial Officer (GlobeNewswire)
  • Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update (GlobeNewswire) +7.92% -6.60%
  • Earnings To Watch: Longeveron Inc (LGVN) Q2 2026 -- GF Value Sees 58% Downside (GuruFocus.com) -6.00%
  • Longeveron Named a Finalist Team and Will Receive a $1,000,000 Milestone 2 Award for the XPRIZE Healthspan Global Competition (GlobeNewswire)
  • Longeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026 (GlobeNewswire)
  • Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors (GlobeNewswire)
  • Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer's Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer's Disease (GlobeNewswire) -6.52%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-12-1.900-1.750-1.9000.290.334
2026Q12026-05-13-1.900-1.775-1.9110.400.334
2025Q42026-03-17-2.300-3.667-2.3740.370.113
2025Q32025-11-04-3.900-2.550-3.9300.140.272
2025Q22025-08-13-3.300-3.500-3.3490.320.423
2025Q12025-05-08-3.400-3.300-3.3520.380.593
2024Q42025-02-28-4.338-3.700-2.7410.600.582
2024Q32024-11-12-3.400-3.900-3.3520.770.402
2024Q22024-08-14-18.300-11.200-18.3010.470.501
2024Q12024-05-14-16.100-20.050-16.1440.550.062
2023Q42024-02-27-25.000-21.333-25.5170.060.213
2023Q32023-11-10-28.000-22.500-27.8770.150.402
2023Q22023-08-11-27.000-24.667-26.6850.220.403
2023Q12023-05-12-22.000-21.330-22.0930.280.303
2022Q42023-03-10-21.000-20.000-21.2010.120.403
2022Q32022-11-14-25.000-22.000-24.9700.270.203

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-90.000-94.500-81.6401.311.30
2022FY-90.000-87.000-89.8231.221.15
2023FY-102-96.333-102.190.710.81
2024FY-26.200-36.867-26.1642.392.16
2025FY-12.900-14.267-12.9001.200.92
2026FY--7.200--2.40
2027FY--5.800--2.37
2028FY--5.600--2.90
2029FY-23.400--216.31
2030FY-35.900--308.61

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-281100.800.800.80
2026Q3S2026-09-172100.560.330.80
2026Q3S2026-09-163200.410.100.80
2026Q3S2026-08-223100.400.100.77
2026Q3S2026-08-184100.400.100.77
2026Q3S2026-08-134000.390.060.77
2026Q3S2026-08-124000.390.060.77
2026Q3S2026-07-284000.390.060.77
2026Q3S2026-05-284110.390.060.77
2026Q3S2026-05-234210.390.060.77
2026Q3S2026-05-144310.390.060.77
2026Q3S2026-05-084300.380.100.77
2026Q3S2026-05-013200.390.100.77
2026Q3S2026-03-182200.440.100.77

Estimate history

EPS, annual-33.167-15.492-19.628-81.64-89.823-102.19-26.164-12.917-10.1507
Period20182019202020212022202320242025TTM
EPS, quarterly-18.301-3.352-2.741-3.352-3.349-3.93-2.374-1.911-1.936
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual2.1355.6395.631.3061.2220.7092.3921.1991.19
Period20182019202020212022202320242025TTM
Sales, quarterly0.4680.7730.6030.3810.3160.1370.3650.3980.287
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.1910.1910.190.2090.210.2511.4892.2933.172
Period20182019202020212022202320242025MRQ
Shares, quarterly0.961.4841.4891.4961.5112.1062.2933.0783.172
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue1.191.202.390.711.221.315.635.642.13
Cost of Goods Sold Incl. D&A1.381.621.471.431.621.634.594.651.45
Gross Profit-0.19-0.420.93-0.72-0.40-0.321.040.990.68
Selling, General and Administrative Excl. Other23.4722.8617.4519.9017.6517.134.823.987.04
Research and Development11.0710.817.188.128.486.181.891.023.88
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-23.66-23.29-16.52-20.63-18.04-17.46-3.78-3.00-6.36
Interest Expense0.000.000.000.000.000.000.010.000.00
Unusual Expense0.000.000.000.701.09-0.210.000.000.00
Net Income Before Taxes-23.47-22.70-15.97-21.41-18.84-17.10-3.72-2.96-6.34
Income Taxes0.000.000.000.000.00-0.060.000.000.00
Consolidated Net Income-23.47-22.70-15.97-21.41-18.84-17.05-3.72-2.96-6.34
Net Income From Continuing Operations-23.47-22.70-15.97-21.41-18.84-17.05-3.72-2.96-6.34
Net Income-23.47-22.70-24.62-22.21-18.84-17.05-3.72-2.96-6.34
EPS (Recurring)-7.48-12.92-26.16-99.95-86.18-82.36-19.63-15.49-33.17
EPS (Basic, Before Extraordinaries)-10.15-12.92-26.16-102.19-89.82-81.64-19.63-15.49-33.17
EPS (Diluted)-10.15-12.92-26.16-102.19-89.82-81.64-19.63-15.49-33.17
EBITDA-22.64-22.06-15.56-19.68-17.15-16.54-2.99-2.23-5.61
Non-Operating Income (Expense)0.180.580.55-0.090.300.140.060.040.02
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.581.682.332.032.346.440.040.140.42
Price To Sales Ratio18.587.426.8141.6955.25192.96---
Gross Margin-15.92-35.3638.67-102.26-32.41-24.8118.4917.4731.88
Operating Margin-1,992.84-1,942.20-690.72-2,909.59-1,476.51-1,336.60-67.12-53.16-297.95
Net Margin-1,977.59-1,893.58-1,029.39-3,132.72-1,541.33-1,305.13-66.09-52.49-296.84
Shares Outstanding3.172.291.490.250.210.210.190.190.19
Market Capitalization10.5210.5225.7628.9867.63252.00242.26--

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.290.400.360.140.320.380.600.77
Cost of Goods Sold Incl. D&A0.330.390.390.280.430.530.320.33
Gross Profit-0.040.01-0.02-0.14-0.12-0.140.290.45
Selling, General and Administrative Excl. Other6.134.795.387.175.285.044.575.10
Research and Development2.972.072.443.592.692.101.751.97
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-6.17-4.78-5.40-7.31-5.40-5.18-4.28-4.65
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-6.07-4.74-5.44-7.22-5.03-5.01-4.08-4.42
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-6.07-4.74-5.44-7.22-5.03-5.01-4.08-4.42
Net Income From Continuing Operations-6.07-4.74-5.44-7.22-5.03-5.01-4.08-4.42
Net Income-6.07-4.74-5.44-7.22-5.03-5.01-4.08-4.57
EPS (Recurring)-1.94-1.91-2.37-3.93-3.35-3.35-2.74-3.35
EPS (Basic, Before Extraordinaries)-1.94-1.91-2.37-3.93-3.35-3.35-2.74-3.35
EPS (Diluted)-1.94-1.91-2.37-3.93-3.35-3.35-2.74-3.35
EBITDA-5.95-4.52-5.12-7.04-5.13-4.76-4.04-4.42
Non-Operating Income (Expense)0.100.04-0.040.090.370.170.200.23
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.370.380.380.450.510.340.391.41
Price To Sales Ratio18.5821.209.689.599.4110.4210.7714.28
Gross Margin-13.593.02-6.03-102.19-37.03-38.0647.6057.96
Operating Margin-2,150.17-1,199.75-1,479.18-5,335.77-1,707.91-1,359.84-709.95-601.42
Net Margin-2,116.03-1,189.95-1,491.51-5,270.80-1,591.14-1,315.22-676.78-590.94
Shares Outstanding3.173.082.292.111.511.501.491.48
Market Capitalization10.5232.0111.6015.8019.6423.1825.7628.78

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments4.6619.235.3619.6635.040.821.874.03
Short Term Receivables0.100.080.110.220.060.420.450.00
Inventories0.000.000.000.000.000.000.000.00
Other Current Assets0.690.310.380.400.280.050.050.13
Total Current Assets5.4519.625.8520.2835.381.292.374.16
Net Property, Plant & Equipment2.353.333.754.484.885.676.484.76
Total Investments and Advances0.000.000.000.000.000.000.000.00
Long-Term Note Receivable0.100.100.200.160.10---
Intangible Assets2.292.402.292.412.331.551.481.35
Other Assets0.080.100.090.180.180.740.250.25
Total Assets10.2625.5612.1827.5142.879.2410.5810.52
Short Term Debt Incl. Current Port. of LT Debt0.660.620.590.560.540.690.490.00
Accounts Payable0.420.100.641.750.651.591.151.21
Other Current Liabilities3.011.862.662.551.531.550.850.66
Total Current Liabilities4.092.583.894.872.713.832.491.86
Long Term Debt0.170.821.452.042.603.453.650.00
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Other Liabilities0.330.270.000.000.000.000.001.84
Total Liabilities4.593.675.346.915.317.286.143.71
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.00
Common Equity5.6721.896.8420.6037.551.964.456.81
Total Shareholders Equity5.6721.896.8420.6037.551.964.456.81
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity5.6721.896.8420.6037.551.964.456.81
Total Liabilities & Stockholders Equity10.2625.5612.1827.5142.879.2410.5810.52
Book Value Per Share2.4714.7027.2598.02179.8710.3223.2735.67
Tangible Book Value Per Share1.4813.0918.1486.56168.692.1615.5228.62
Full-Time Employees38262519181212-
Price to Book Ratio1.011.184.312.746.7110.80--
Return on Assets-126.77-84.66-107.90-53.52-65.42-37.54-28.05-
Return on Equity-164.75-111.20-156.05-64.77-86.28-116.24-52.58-
Return on Invested Capital-388.50-70.33-258.33-83.18-42.44-68.77-36.55-92.99
Quick Ratio1.337.601.504.1713.060.340.952.24
Current Ratio1.337.601.504.1713.060.340.952.24

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-23.47-22.70-15.97-21.41-18.84-17.05-3.72-2.96-6.34
Depreciation1.011.230.960.950.890.910.790.770.75
Other Funds (Non Cash)1.671.772.392.543.737.580.080.140.42
Funds from Operations-20.79-19.70-12.63-17.93-14.21-8.55-2.85-2.05-5.17
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital0.411.06-1.24-1.080.24-1.090.49-0.34-0.01
Cash from Operating Activities-20.37-18.64-13.87-19.00-13.97-9.64-2.36-2.39-5.18
Capital Expenditures-0.30-0.59-0.99-0.69-0.86-1.31-0.26-0.13-0.21
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.090.000.000.00
Purchase or Sale of Investments0.000.000.358.880.18-9.470.000.000.00
Purchase of Investments0.000.000.000.000.00-9.470.000.000.00
Sale Or Maturity of Investments0.000.000.358.880.180.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources-0.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.30-0.59-0.648.19-0.68-10.70-0.26-0.13-0.21
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock19.804.9829.065.440.0045.811.100.351.35
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock19.804.9829.065.440.0045.811.100.351.35
Proceedsfrom Stock Options18.444.9812.875.340.0045.191.100.351.35
Issuance or Reduction of Debt, Net0.000.000.000.000.00-0.190.430.000.00
Change in Long Term Debt0.000.000.000.000.00-0.150.390.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.390.000.00
Reduction of Long Term Debt0.000.000.000.000.00-0.150.000.000.00
Net Financing Active Other Cash Flow0.62-0.31-0.27-0.17-0.51-0.450.050.000.00
Other Financing Activities Uses-0.27-0.31-0.37-0.17-0.51-0.450.000.000.00
Cash from Financing Activities20.424.6728.795.26-0.5145.171.580.351.35
Net Change in Cash-0.26-14.5714.28-5.55-15.1524.84-1.05-2.17-4.04
Free Cash Flow-20.53-18.89-14.52-19.30-14.54-9.97-2.50-2.43-5.27
Preferred Dividends (Cash Flow)-0.00--0.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments10.0815.764.669.2410.3314.33
Short Term Receivables0.070.070.100.050.030.03
Inventories0.000.000.000.000.000.00
Other Current Assets1.181.030.691.040.900.92
Total Current Assets11.3216.865.4510.3411.2715.28
Net Property, Plant & Equipment1.952.102.352.732.963.08
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets2.202.242.292.312.322.29
Other Assets0.010.020.080.080.100.10
Total Assets15.4921.2110.2615.5616.7520.85
Short Term Debt Incl. Current Port. of LT Debt0.580.690.660.650.640.63
Accounts Payable0.630.290.421.080.700.37
Other Current Liabilities3.093.363.013.211.951.73
Total Current Liabilities4.314.344.094.943.282.72
Long Term Debt0.000.060.170.340.500.66
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.780.780.330.320.310.30
Total Liabilities5.085.184.595.594.093.69
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity10.4016.035.679.9712.6617.16
Total Shareholders Equity10.4016.035.679.9712.6617.16
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity10.4016.035.679.9712.6617.16
Total Liabilities & Stockholders Equity15.4921.2110.2615.5616.7520.85
Book Value Per Share3.285.212.474.738.3811.47
Tangible Book Value Per Share2.594.481.483.646.849.94
Full-Time Employees--38---
Price to Book Ratio1.012.002.041.591.551.35
Return on Assets-145.64-106.66-126.77-93.88-102.59-110.81
Return on Equity-203.61-135.18-164.75-119.92-134.50-167.57
Return on Invested Capital-58.38-29.44-93.16-70.09-38.22-28.12
Quick Ratio2.633.881.332.093.435.61
Current Ratio2.633.881.332.093.435.61

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-6.07-4.74-5.44-7.22-5.03-5.01
Depreciation0.220.250.280.260.260.42
Other Funds (Non Cash)0.370.380.470.450.510.34
Funds from Operations-5.48-4.11-4.69-6.51-4.25-4.25
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.17-0.27-0.601.450.66-0.45
Cash from Operating Activities-5.65-4.37-5.30-5.05-3.60-4.70
Capital Expenditures-0.10-0.02-0.06-0.12-0.26-0.15
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.00--0.00
Cash from Investing Activities-0.10-0.02-0.06-0.12-0.26-0.15
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.1414.690.844.140.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.1414.690.844.140.000.00
Proceedsfrom Stock Options0.0513.410.844.140.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.060.80-0.06-0.06-0.13-0.06
Other Financing Activities Uses-0.06-0.09-0.06-0.06-0.13-0.06
Cash from Financing Activities0.0715.490.784.08-0.13-0.06
Net Change in Cash-5.6811.10-4.58-1.09-3.99-4.91
Free Cash Flow-5.76-4.37-5.30-5.11-3.76-4.72

Revenue breakdown

Clinical Trial2024: 1.40M 2025: 954.00K
Contract Manufacturing2024: 487.00K 2025: 222.00K
Contract Manufacturing Lease2024: 503.00K 2025: 23.00K
United States2024: 2.39M 2025: 1.20M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-306.31%0.2M2.5M106.48K
2026-10-152.94%0.1M2.5M97.10K
2026-09-304.29%0.1M2.5M90.85K
2026-09-158.62%0.2M2.5M46.02K
2026-08-319.16%0.2M2.5M41.43K
2026-08-146.47%0.2M2.6M32.54K
2026-07-315.97%0.2M2.6M30.95K
2026-07-155.86%0.2M2.6M36.70K
2026-06-306.12%0.2M2.6M49.17K
2026-06-157.02%0.2M2.6M108.29K
2026-05-298.73%0.2M2.5M550.83K
2026-05-159.65%0.2M2.4M556.01K
2026-04-3014.66%0.3M1.8M559.13K
2026-04-1515.05%0.3M1.9M562.10K
2026-03-3112.47%0.2M1.9M548.08K
2026-03-1323.60%0.5M1.9M487.72K
2026-02-278.71%0.2M1.8M36.15K
2026-02-137.08%0.1M1.8M30.45K
2026-01-307.86%0.1M1.6M35.54K
2026-01-159.68%0.1M1.1M39.48K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-058-KCurrent report2026-11-01SEC
2026-11-05SCHEDULE 13G/ASEC
2026-10-268-KCurrent report2026-10-26SEC
2026-10-148-KCurrent report2026-10-07SEC
2026-10-054Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-054Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-054Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-054Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-054Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-09-238-KCurrent report2026-09-16SEC
2026-09-148-KCurrent report2026-09-11SEC
2026-09-10SCHEDULE 13GSEC
2026-08-254Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-253Initial statement of beneficial ownership of securities2026-08-17SEC
2026-08-248-KCurrent report2026-08-20SEC
2026-08-214Statement of changes in beneficial ownership of securities2026-08-19SEC
2026-08-214Statement of changes in beneficial ownership of securities2026-08-19SEC
2026-08-214Statement of changes in beneficial ownership of securities2026-08-19SEC
2026-08-214Statement of changes in beneficial ownership of securities2026-08-19SEC
2026-08-214Statement of changes in beneficial ownership of securities2026-08-19SEC
2026-08-214Statement of changes in beneficial ownership of securities2026-08-19SEC
2026-08-214Statement of changes in beneficial ownership of securities2026-08-19SEC
2026-08-214Statement of changes in beneficial ownership of securities2026-08-19SEC
2026-08-214Statement of changes in beneficial ownership of securities2026-08-19SEC
2026-08-214Statement of changes in beneficial ownership of securities2026-08-19SEC
2026-08-214Statement of changes in beneficial ownership of securities2026-08-19SEC
2026-08-198-KCurrent report2026-08-17SEC
2026-08-13SCHEDULE 13G/ASEC
2026-08-128-KCurrent report2026-08-12SEC
2026-08-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
MILLENNIUM MANAGEMENT LLC4.28%
Logos Global Management LP4.07%
VANGUARD CAPITAL MANAGEMENT LLC1.84%
GEODE CAPITAL MANAGEMENT, LLC0.79%
BlackRock, Inc.0.71%
JANE STREET GROUP, LLC0.60%
VANGUARD FIDUCIARY TRUST CO0.44%
Mariner, LLC0.40%
ADAR1 Capital Management, LLC0.34%
Beacon Pointe Advisors, LLC0.32%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND1.14%
VANGUARD EXTENDED MARKET INDEX FUND0.57%
Fidelity Extended Market Index Fund0.42%
Fidelity Total Market Index Fund0.08%
Fidelity Series Total Market Index Fund0.06%
Fidelity Nasdaq Composite Index Fund0.01%

OakChart. LGVN. Cached 15 minutes.

Some panels did not load: insider.